Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New president & CEO at Marinus Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Marinus Pharmaceuticals (US), a developer of therapeutics to treat neurological, psychiatric and pain disorders, has appointed John Krayacich president and chief executive officer. He will be responsible for leading the company's drug and business development for ganaxolone, an adult and paediatric epilepsy candidate in Phase II development, and chelerythrine, a preclinical schizophrenia candidate. Mr Krayacich most recently was with Novartis Pharmaceuticals, where he served as global programme head for the antidepressant agomelatine, and vice-president and global head of neuroscience project management.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts